The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1479-1485

  Agnarsson, Hjalmar Ragnar ^a   Johannsson, Gudmundur ^b   Ragnarsson, Oskar ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; ADULT; AGED; BONE DENSITY; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84898491093     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3851     Document Type: Article

References (32)

1. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res . 2001;16:398-405.
2. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab . 1994;78:669-674.
3. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol . 1997;137: 240-245.
4. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushings syndrome: a prospective, long-term study. Eur J Endocrinol . 2006;154:109-118.
5. Vestergaard P, Lindholm J, Jorgensen JO, et al. Increased risk of osteoporotic fractures in patients with Cushings syndrome. Eur J Endocrinol . 2002;146:51-56.
6. Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab . 2009; 94:3207-3214.
7. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos Int . 2007;18:1319-1328.
8. Ragnarsson O, Nystrom HF, Johannsson G. Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clin Endocrinol (Oxf) . 2012;76:246-252.
9. Tritos NA, Greenspan SL, King D, et al. Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab . 2011;96:1516-1523.
10. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med . 2011;365:62-70.
11. Kaltsas G, Makras P. Skeletal diseases in Cushings syndrome: osteoporosis versus arthropathy. Neuroendocrinology 2010;92(suppl 1):60-64.
12. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev . 2008;29:535-559.
13. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab . 1996;81:2865-2873.
14. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev . 1998;19:55-79.
15. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev . 2004;25:831-866.
16. Cooper MS, Blumsohn A, Goddard PE, et al. 11-Hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab . 2003;88:3874-3877.
17. Ramli ES, Suhaimi F, Asri SF, Ahmad F, Soelaiman IN. Glycyrrhizic acid (GCA) as 11-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis. J Bone Miner Metab . 2013;31:262-273.
18. Moore JS, Monson JP, Kaltsas G, et al. Modulation of 11-hydroxysteroid dehydrogenase isozymes by growth hormone and insulinlike growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab . 1999;84:4172-4177.
19. Weaver JU, Thaventhiran L, Noonan K, et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) . 1994;41: 639-648.
20. Gelding SV, Taylor NF, Wood PJ, et al. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) . 1998;48:153-162.
21. Giavoli C, Libe R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitaryadrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab . 2004;89:5397-5401.
22. Johannsson G, Rosen T, Bengtsson BA. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) . 1997;47:571-581.
23. Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res . 2003;60:53-60.
24. Lovas K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addisons disease: effects on bone. Eur J Endocrinol . 2009;160:993-1002.
25. Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab . 2012;97:85-92.
26. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab . 2006;91:3954-3961.
27. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med . 1994;120:207-210.
28. Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) . 2010;72:297-304.
29. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab . 2007; 92:3912-3922.
30. Feldt-Rasmussen U, Abs R, Bengtsson BA, et al. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushings disease. Eur J Endocrinol . 2002;146:67-74.
31. Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushings disease. Clin Endocrinol (Oxf) . 2004;60:550-559.
32. Tritos NA, Hamrahian AH, King D, et al. Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency-a KIMS database analysis. Clin Endocrinol (Oxf) . 2013;79:178-184.